Global Carrier Screening Market – Industry Trends and Forecast to 2029

Global Carrier Screening Market, By Test Type (Molecular Screening Test, Biochemical Screening Test), Disease Type (Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell Disease, Spinal Muscular Atrophy, Other Autosomal Recessive Genetic Disorders),Medical Condition(Pulmonary Conditions, Hematological Conditions, Neurological Conditions, Others), Technology(DNA Sequencing, Polymerase Chain Reaction, Microarrays, Others),End Use (Hospitals, Reference Laboratories, Physician Offices and Clinics, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

According to the Centers for Disease control and Prevention in 2020, sickle cell disease approximately affects 100,000 Americans. Thus, as the prevalence of genetic diseases is increasing every year, the usage of carrier screening is also expected to increase during the forecast period.

Data Bridge Market Research analyses that the carrier screening market which was USD 1736.02 million in 2021, would rocket up to USD 5460.12 million by 2029, and is expected to undergo a CAGR of 15.40% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

The diagnosis of a faulty chromosome or genetic condition in a carrier who receives one abnormal gene from one of its parents is known as carrier screening. Carriers of a defective gene often do not show symptoms of a genetic illness. The carrier screening market is growing due to an increase in the frequency of genetic illnesses, increased test availability and affordability, and more high-end product introductions.

Carrier Screening Market Dynamics

Drivers

• Increasing emphasis on early disease detection and prevention

The increased emphasis on early illness identification and prevention, the high risk of chromosomal abnormalities, and technological developments in carrier screening, such as the introduction of extended carrier screening panels, are all contributing to the market's growth. The growing awareness of carrier screening is projected to open up a slew of new growth prospects for industry competitors.

• Rise in genetic diseases

Increased emphasis on early illness identification and prevention, surge in demand for personalised medication, and rise in applications of screening tests in genetic disorders are likely to propel the worldwide carrier screening market forward. Inherited diseases such as cystic fibrosis, sickle cell anaemia, and Tay–Sachs disease are examples of genetic diseases. Carrier testing for disorders like these might reveal a couple's risk of delivering a kid with a genetic issue. Prenatal screening or carrier screening can discover several genetic abnormalities early in pregnancy. As a result, the market is growing due to an increase in demand for safe and effective carrier tests.
 

• Recent technical developments

Recent technological developments have facilitated the quick adoption of technology. Carrier screening is a set of genetic testing that determines whether a person is a possible carrier of genetic illnesses such cystic fibrosis (CF), Down's syndrome, Fragile X syndrome, sickle cell anaemia, and spinal muscular atrophy (SMA). Carrier screening tests are commonly used by couples planning to become pregnant to identify the likelihood of transferring genetic abnormalities to their kid. This research aims to figure out how carrier screening can help support the current era of precision medicine in the realm of reproductive health.

Opportunities

The decline in the cost of sequencing, the growing emphasis on early identification and prevention of complex genetic illnesses, and the increasing maternal age leading to pregnancy problems are all projected to propel the carrier screening industry forward. The growing emphasis on early disease identification and prevention and the expanding use of screening tests in genetic disorders are likely to propel the carrier screening market forward over the forecast period.

Restraints/Challenges

However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers.

This carrier screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the carrier screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 impact on Carrier Screening Market

COVID-19 had a substantial impact on market expansion. Due to the unexpected enforcement of the lockdown restriction across the globe, the global carrier screening industry experienced growth constraints, resulting in a decrease in patient influx to genetic counsellors. However, during the post-pandemic period, the limits were eased, which helped the industry thrive.

Recent Development

• In January 2022 Mitera has announced the availability of its Peaches& Me and 23 Pears at-home reproductive genetic testing kits in all 50 states. It looks for diseases like Down syndrome.
• In June 2021 The Galleri blood est, a revolutionary multi-cancer screening test, was launched by Grail. The test was designed to examine those who may already have an increased cancer risk, such as adults over 50.

Global Carrier Screening Market Scope

The carrier screening market is segmented on the basis of test type, medical condition, technology and disease type. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Screening Test
• Biochemical Screening Test

Disease Type

• Cystic Fibrosis
• Tay-Sachs
• Gaucher Disease
• Sickle Cell Disease
• Spinal Muscular Atrophy
• Other Autosomal Recessive Genetic Disorders

Medical Condition

• Pulmonary Conditions
• Hematological Conditions
• Neurological Conditions
• Others

 Technology

• DNA Sequencing
• Polymerase Chain Reaction
• Microarrays
• Others

End User

• Hospitals
• Reference Laboratories
• Physician Offices and Clinics
• Others

Carrier Screening Market Regional Analysis/Insights

The carrier screening market is analysed and market size insights and trends are provided by country, test type, medical condition, technology and disease type as referenced above.

The countries covered in the carrier screening market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market during the forecast period, followed by Europe due to growth which can be attributed to several factors, such as the presence of well-established healthcare systems in the US and Canada, wide access to advanced screening techniques (such as DNA sequencing), recommendations for carrier screening.

Asia-pacific is expected to grow in the region due to high and growing demand for the early detection of genetic disorders among the population, availability of mass genetic testing programs, increasing awareness campaigns, and the high incidence of chromosomal disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Carrier Screening Market Share Analysis

The carrier screening market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to carrier screening market.

Some of the major players operating in the carrier screening market are:

• Eurofins Scientific (Luxembourg)
• Invitae Corporation (U.S)
• Opko Health Inc. (U.S)
• Luminex Corporation (U.S)
• Fulgent Genetics (U.S)
• Quest Diagnostics (U.S)
• Sema4 OpCo, Inc. (U.S)
• Myriad Genetics (U.S)
• Illumina Inc. (U.S)
• Thermo Fisher Scientific Inc. (U.S)
• MedGenome (U.S)
• Myriad Genetics Inc. (U.S)
• Natera Inc. (U.S)
• Gene By Gene Ltd. (U.S)
• Laboratory Corporation of America Holdings (U.S)
• Mount Sinai Genomics Inc. (U.S)
• Otogenetics Corporation (U.S)